Stem cell-based regenerative therapy to treat heart failure
30 June, 2023A new study saw pluripotent (immature) stem cells cultivated in the laboratory to grow into heart muscle precursor cells, which can develop into various types of heart cells.
Needle-free vaccine patch facility opens in Brisbane
26 June, 2023The custom-built, 5500 m2 Vaxxas Biomedical Facility will support the production of needle-free vaccine patches for future late-stage clinical trials and commercial products.
Selective targeting of cancer cells in new treatment approach
26 June, 2023Finding a way to make drugs act more selectively on cancer cells is the key to improving treatment success while reducing toxicity in children treated for high-risk leukaemia.
Personalised vaccines trialled for skin cancer treatment
16 June, 2023An mRNA vaccine tailored to suit an individual's tumour genetics was added to common immunotherapy treatment, with promising results.
UQ partners with US university to create homegrown vaccines
08 June, 2023The University of Queensland and Emory University have committed to scaling up their collaboration to focus on pandemic preparedness and regional disease prevention.
Oral medication for Crohn's disease approved by FDA
07 June, 2023Patients with moderate-to-severe Crohn's disease now have a new treatment option to suppress their intestinal inflammation and help them maintain their relief.
Nanoparticle used to deliver brain cancer drug
05 June, 2023The new silica nanoparticle can be loaded with temozolomide, a small molecule drug used to treat tumours known as glioblastoma.
Sydney Uni spinout lands deal to develop psychiatric drugs
10 May, 2023Kinoxis Therapeutics has announced a strategic partnership with Boehringer Ingelheim for the development of first-in-class oxytocin-targeting precision psychiatry treatments.
Cognitive decline slowed in Alzheimer's drug trial
08 May, 2023The phase 3 drug trial from Eli Lilly and Company indicated significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's.
Micropore Pathfinder for development of RNA/LNP therapeutics and vaccines
01 May, 2023Harnessing the capabilities of Micropore's AXF mini, together with intuitive software, the AXF Pathfinder is a compact benchtop unit for discovery, development and phase 1 clinical development through to full GMP manufacture of nucleic acid therapeutics and vaccines.
Opportunities for biotech await in the Amazon rainforest
01 May, 2023 by Emily Newton*As deforestation continues in the Amazon rainforest, humanity could permanently lose an untold number of life-changing drugs.
Flexible gold sensor promising for medical implants
27 April, 2023Researchers have produced a film-like sensor that is both flexible and sensitive enough to enable a more streamlined future for electronic medical implants.
Wireless pacemakers may be safe for children
26 April, 2023Wireless or leadless pacemakers, commonly implanted in adults, may be a safe and effective short-term option for children with slow heartbeats.
An RNA encapsulation facility in your hand
18 April, 2023The Micropore AXF (Advanced Cross Flow) range is expected to make a significant contribution to improving the performance of entire nanoparticle manufacturing processes.
Creating a genetic medicine manufacturing ecosystem: part 4
10 April, 2023 by Peter DavisWe are on the precipice of an explosion in local manufacturing of genetic medicines on a scale never seen before, with global equitable access.
